目的 以銀杏葉提取物注射劑為對照藥，系統(tǒng)評價疏血通注射液治療急性腦梗死的臨床療效和安全性。方法 檢索PubMed、中國知網(wǎng)（CNKI）、中國生物醫(yī)學全文數(shù)據(jù)庫（CBM）、維普網(wǎng)（VIP）、萬方數(shù)據(jù)庫，收集疏血通注射液對比銀杏葉提取物治療急性腦梗死的隨機對照研究（RCTs），檢索年限為從建庫至2016年7月。由2名研究者獨立提取數(shù)據(jù)、評價質(zhì)量，并交叉核對，采用RevMan 5.2 軟件進行Meta分析。結(jié)果 納入11項RCTs，1 338例患者。Meta分析結(jié)果顯示，疏血通注射液的臨床總有效率[RR=1.17，95%CI（1.11，1.23），P<0.01]，降低神經(jīng)功能缺損評分[MD=-4.46，95%CI（-6.07，-3.25），P<0.01]和提高生活能力評分[MD=13.98，95%CI（11.30，16.65），P<0.01]均顯著優(yōu)于銀杏葉提取物制劑，兩組均未發(fā)生嚴重不良反應。結(jié)論 現(xiàn)有證據(jù)表明疏血通注射液治療急性腦梗死的臨床療效、改善神經(jīng)功能缺損和生活能力均優(yōu)于銀杏葉提取物。

Objective Using Gink biloba extract injection as control drug, to systematically review the efficacy and safety of Shuxuetong Injection in the treatment of acute cerebral infarction. Methods Database including PubMed, Medline, CNKI, VIP and WanFang Data were searched to collect randomized controlled trials (RCTs) about Shuxuetong Injection versus G. biloba extract injection in the treatment of acute cerebral infarction from database setup time to July of 2016. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. The meta-analysis was conducted by RevMan 5.2 software. Results Total of 11 RCTs, 1 338 patients were included. Meta-analysis showed that Shuxuetong Injection was significantly better than G. biloba extract injection in clinical total effective rate[RR=1.17, 95%CI(1.11, 1.23), P<0.01], reducing neurological deficit score[MD=-4.46, 95%CI (-6.07, -3.25), P<0.01] and improving life ability score[MD=13.98, 95%CI (11.30, 16.65), P<0.01], there was no serious adverse reaction in both groups. Conclusion Current evidence shows that Shuxuetong Injection is effective and safe in the treatment of acute cerebral infarction better than G. biloba extract injection.

河北省衡水市科學技術(shù)研究與發(fā)展計劃課題項目（衡科字[2016]3號-15022）